Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls
NCT00005108 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2008-03-04
Summary
This study will determine the effects of hormone replacement therapy (estrogen alone or estrogen and progesterone) on the walls of arteries in postmenopausal women. Inflammation and stiffness of artery walls are two risk factors for atherosclerosis-deposits of fatty substances (plaques) that can block the vessel, causing a heart attack or stroke. Estrogen raises the levels of certain substances in the blood that cause vessel inflammation and lowers the levels of others. This study will measure the net effects of estrogen on artery wall inflammation and stiffness.
Postmenopausal women in good health may participate in this study. Volunteers will be screened for eligibility with a complete medical history, heart examination, and blood tests. Participants will be randomly assigned to receive either: 1) hormone therapy (estradiol 2 mg daily alone for women who have had a hysterectomy or estradiol plus micronized progesterone 200 mg daily for women with an intact uterus); or 2) placebo (look-alike pills that contain no active drug). Women in both groups will take pills for 3 months, then no pills for 1 month, and then will crossover to the alternate therapy for 3 months (i.e., those in the original placebo group will take hormones, and those in the hormone group will take placebo). At the end of each 3-month treatment period, participants will undergo the following procedures to assess blood vessel inflammation and stiffness:
1. Blood tests - 60 cc (about 2 ounces) of blood will be drawn to measure levels of hormones, cholesterol, and substances in the blood that indicate inflammation of the vessels.
2. Ultrasonography - an ultrasound probe will be applied gently on the neck to image the right and left carotid arteries (arteries in the neck that lead to the brain). During the procedure, the heart's electrical activity will also be monitored with an electrocardiogram and a blood pressure cuff will be wrapped around the arm to obtain blood pressure measurements every 5 minutes.
3. Magnetic resonance imaging (MRI) - Images of the carotid arteries are taken while the volunteer lies on a table in a narrow cylinder containing a magnetic field. A padded sensor called an MRI coil is placed over the neck and earplugs are placed in the ears to muffle the loud noise of the machine during scanning. During the second half of the exam, gadolinium is injected through a catheter (thin, flexible tube) inserted into a vein. Gadolinium is a contrast agent that is used to brighten the scan images.
Information from this study will increase knowledge about the effects of estrogen on vessel wall inflammation. As such, it may be used in the future to help guide decisions about chronic hormone replacement therapy in postmenopausal women.
Conditions
- Atherosclerosis
- Healthy
- Vascular Disease
Interventions
- DRUG
-
Estradiol
- DRUG
-
Progesterone
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
lead NIH
Study Design
- Purpose
- TREATMENT
Eligibility
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-04-30
- Completion
- 2002-01-31
Countries
- United States
Study Locations
More Related Trials
-
Postmenopausal Hormone Therapy in Unstable Angina
NCT00000601 ·Status: COMPLETED ·Phase: PHASE3
-
Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women
NCT00001752 ·Status: COMPLETED ·Phase: PHASE2
-
Discontinuation of Postmenopausal Hormone Therapy: Impact on the Cardiovascular System and Quality of Life
NCT04050592 ·Status: UNKNOWN ·Phase: PHASE4
-
Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)
NCT00000559 ·Status: COMPLETED ·Phase: PHASE3
-
Estrogen Alternatives Study
NCT00108238 ·Status: COMPLETED ·Phase: PHASE4
-
Menopause Effects on Vascular Function
NCT03236545 ·Status: COMPLETED ·Phase: NA
-
Estrogen, HDL, and Coronary Heart Disease in Women
NCT00083824 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Reduction of Triglycerides in Women on Hormone Replacement Therapy
NCT00023543 ·Status: COMPLETED ·Phase: PHASE2
-
Postmenopausal Progestins, MI and Stroke
NCT00005220 ·Status: COMPLETED
-
Estrogen, Cytokines and Heart Failure in Women
NCT00041431 ·Status: COMPLETED ·Phase: NA
-
Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy (HRT)
NCT00668603 ·Status: COMPLETED ·Phase: NA
-
Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women
NCT02042196 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Stroke and MI in Users of Estrogen/Progestogen
NCT00005466 ·Status: COMPLETED
-
Myocardial Infarction and Non-contraceptive Estrogen Use
NCT00005185 ·Status: COMPLETED
-
Midlife Cholesterol Study
NCT00361075 ·Status: COMPLETED ·Phase: PHASE4
-
The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.
NCT03097120 ·Status: COMPLETED ·Phase: PHASE3
-
Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination
NCT00251082 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
NCT01942668 ·Status: COMPLETED ·Phase: PHASE3
-
A New Hormone Replacement Paradigm: Physiologic Restoration Study
NCT04190927 ·Status: UNKNOWN ·Phase: PHASE4
-
Perimenopausal Estrogen Replacement Therapy Study
NCT01308814 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Hormone Therapy Effects on CVD Risk Factors
NCT00006313 ·Status: COMPLETED
-
Hormone Estradiol Replacement Therapy Additional Herbals
NCT02618148 ·Status: COMPLETED ·Phase: PHASE4
-
Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women
NCT03018366 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function
NCT03112226 ·Status: COMPLETED ·Phase: NA
-
Estrogen Diastolic Heart Failure
NCT02693002 ·Status: TERMINATED ·Phase: PHASE4